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Abstract Transplant recipients can be sensitized against
allo-HLA antigens by previous transplantation, blood
transfusion, or pregnancy. While there is growing aware-
ness that multiple components of the immune system can
act as effectors of the alloresponse, the role of infectious
pathogen exposure in triggering sensitization and allograft
rejection has remained a matter of much debate. Here, we
describe that exposure to pathogens may enhance the im-
mune response to allogeneic HLA antigens via different
pathways. The potential role of allo-HLA cross-reactivity
of virus-specific memory T cells, activation of innate im-
munity leading to a more efficient induction of the adap-
tive alloimmune response by antigen-presenting cells, and
bystander activation of existing memory B cell activation
will be discussed in this review.
Keywords Infection . HLA . Alloreactivity . Heterologous
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Introduction
A substantial portion of the pre-existing T cell repertoire is al-
ready alloreactive even in non-sensitized individuals, with
pre-existing memory Tcells capable of responding to alloanti-
gens. When transplant immunologists quantified the
alloreactive T cell repertoire, the proportion of T cells
responding to the graft was described as “inordinate” as the
number and proportion of T cells responding to donor HLA
antigens was found to be vastly greater than that of responses
to pathogen-derived antigens (Lombardi et al. 1990; Macedo
et al. 2009; Suchin et al. 2001). The pre-transplant frequency
of donor-specific IFNγ-producing lymphocytes does correlate
with the risk of post-transplant rejection episodes (Heeger et al.
1999). It has been postulated that this high frequency of mem-
ory T cells able to respond to allo-HLA even in non-sensitized
individuals could be attributable to cross-reactivity from
virus-specific memory T cells. Recent in vitro experiments
strongly suggest this may indeed be the case (Amir et al.
2010; D’Orsogna et al. 2011a; D’Orsogna et al. 2011b).
B cell sensitization is revealed by the presence of HLA
antibodies which are rarely detected in non-sensitized individ-
uals. However, recent evidence confirms that HLA antibody
production can also be associated with infections and
vaccination.
The role of the innate immune system in solid organ trans-
plant rejection has not been extensively studied. However, it
has become clear that also following pathogen infection acti-
vation of innate immunity could contribute significantly to the
development of acute and/or chronic rejection and impacts
alloimmunity.
In this paper, we review how exposure to infectious agents
could be associated with increased risk of MHC-specific
This article is published in the Special Issue MHC Genes and Their
Ligands in Health and Disease with Editor Prof. Ronald Bontrop.
* Frans H.J. Claas
fhjclaas@lumc.nl
1 Department of Clinical Immunology and Pathwest, Fiona Stanley
Hospital and University of Western Australia, Perth, Australia
2 Department of Immunohaematology and Blood Transfusion, Leiden
University Medical Center, Leiden, The Netherlands




allorecognition and poor graft outcome in the solid organ
transplant setting. Infectious pathogens might induce
alloreactivity directly via molecular mimicry (“heterologous
immunity”) or alternatively by providing co-stimulatory fac-
tors for bystander activation of alloreactive leukocytes. Taken
together, recent evidence supports the hypothesis that infec-
tious pathogens may have significant impact on the rate of
solid organ rejection. This is also consistent with the notion
that infectious pathogens might be a major obstacle to the
induction of successful transplant tolerance.
Allo-HLA cross-reactivity by virus-specific memory T
cells
Direct alloreactivity occurs when recipient T cells directly
recognize donor cells expressing mismatched HLA mole-
cules, and is usually associated with acute T cell-mediated
rejection. The clinical importance of alloreactive T cells acti-
vated following transplantation is well documented in the im-
mediate post-transplant period. However, donor cells do con-
tinue to express mismatched MHC molecules which could be
recognized by directly alloreactive Tcells at any time. Directly
reactive memory T cell responses to allogeneic MHC may be
associated with acute rejection and chronic allograft nephrop-
athy, and are a potent barrier to transplantation tolerance.
In humans, acute rejection has been associated with vary-
ing viral infections, and CMV prophylaxis with oral ganciclo-
vir is associated with improved long-term renal graft outcome
(Kliem et al. 2008). CMV disease is also associated with in-
creased risk of GvHD in the bone marrow transplant setting
(Cantoni et al. 2010). The fact that cord blood T cells are less
able to mediate GvHD than marrow derived Tcells because of
their naive status also supports the theory that memory T cells
generated after pathogen exposure are able to directly elicit
alloreactive responses (Byrne et al. 1988; Risdon et al. 1995).
The presence of in vivo pathogen-induced alloreactive T
cell memory is a potent barrier to transplantation tolerance in
mice. Many strategies have been used to successfully induce
transplant tolerance in mice, most of which primarily block
co-stimulatory pathways such as CD80/CD86/CD28,
CD40/CD154, ICOS/ICOSL, or OX40/OX40L among
others. For example, donor-specific transfusion and
anti-CD154 antibody readily induce tolerance in
pathogen-free mice. However, this protocol fails with
peri-operative infection with Listeria monocytogenes as the
pathogen induces memory T cells which abrogate the induc-
tion of transplant tolerance (Wang et al. 2008). Furthermore,
Adams et al., in an elegant set of experiments, were able to
demonstrate a viral dose effect whereby mice previously ex-
posed to multiple viral infections were refractory to tolerance
induction and rejected their allografts, whereas tolerance
could be induced in naive mice or single pathogen-exposed
mice (Adams et al. 2003b). Taken together, these experiments
underline the ability of pathogen infection to have a detrimen-
tal influence on graft survival and/or tolerance induction.
Human EBV-specific clones are cross-reactive
against allo-HLA-B*44:02 via molecular mimicry
One potential explanation for the high frequency of
alloreactive T cells in non-sensitized individuals is the ability
of pre-existing virus-specific Tcells to cross-react with alloge-
neic HLA molecules, a phenomenon termed molecular mim-
icry or heterologous immunity. To investigate the ability of
virus-specific T cells to exert allo-HLA reactivity,
virus-specific T cell lines or clones have been tested against
panels of donor cells expressing HLA class I and II molecules.
EBV EBNA3A-specific T cell clones which are selected to
recognize the immunodominant peptide FLRGRAYGL pre-
sented on HLA-B*08:01 also recognize allogeneic
HLA-B*44:02 and HLA-B*44:05 to which the individual
has never been exposed (Burrows et al. 1994; D’Orsogna
et al. 2009; Macdonald et al. 2009). Despite extensive poly-
morphism between HLA-B*08:01, HLA-B*44:02, and
HLA-B*44:05 and the disparate repertoire of both viral and
allo-peptides, the Epstein-Barr virus (EBV) EBNA3A-specific
T cell receptor (TCR, generated against the B*08:01-restricted
EBV epitope FLRGRAYGL) engages both B*44:02 or
B*44:05 allotypes presenting the self-peptide EEYLQAFTY
(from ABCD3 gene) identically, demonstrating intricate mim-
icry between the peptide-HLA (pHLA) complexes (Archbold
et al. 2006; Macdonald et al. 2009). Therefore, virus-specific
memory T cells can break the law of HLA restriction and
directly recognize foreign HLA molecules from unrelated
(allogeneic) individuals (Amir et al. 2010; Archbold et al.
2006; D’Orsogna et al. 2009; D’Orsogna et al. 2010;
D’Orsogna et al. 2011a; Macdonald et al. 2009).
Allo-HLA reactivity by virus-specific memory T cells is
common
The high frequency of allogeneic HLA (allo-HLA)
cross-reactivity by virus-specific memory T cells has been con-
firmed by our group and others (Amir et al. 2010; Burrows et al.
1994; D’Orsogna et al. 2009; D’Orsogna et al. 2010;
Macdonald et al. 2009; Rist et al. 2009; Umetsu et al. 1985).
Specific allo-HLA cross-reactivity has been shown for EBV,
cytomegalovirus (CMV), varicella zoster virus (VZV), and in-
fluenza A virus-specific T cells, and the cross-reactivity is me-
diated by the same T cell receptor (TCR) (Amir et al. 2010;
D’Orsogna et al. 2010; D’Orsogna et al. 2012; D’Orsogna et al.
2011a). For example, a CMV pp50/HLA-A1-restricted T cell
clone with TCR Vβ3 usage cross-reacts with allogeneic
HLA-A*11:01 and a VZV IE62/HLA-A2-specific T cell clone
with TCR Vβ14 usage cross-reacts with allogeneic
HLA-B*55:01 (Amir et al. 2010). Cross-reactivity for HLA
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class I-restricted T cell clones with allogeneic HLA class II
molecules has also been reported (Amir et al. 2010; Rist et al.
2009). It has been shown that 80% of T cell line lines and 45%
of virus-specific T cell clones cross-react (in vitro) with at least
one allogeneic HLA molecule (Amir et al. 2010). The
allo-HLA cross-reactivity of virus-specific CD8+ T cells is ex-
quisitely dependent on the combination of viral cognate pep-
tide, the restricting HLA molecule, and the TCR Vβ usage of
the Tcell. Therefore, molecular mimicry could underpin human
T cell alloreactivity.
Despite a growing awareness of the potential ability of
virus-specific T cells to mediate alloimmunity, their involve-
ment in clinical human allograft rejection remains to be proven.
Nguyen et al. detected a public CMV-specific CD8 T cell
c l o n o t y p e (NLV-HLA-A2 r e s t r i c t e d ; TCRαβ
TRAV3TRAJ31_TRBV12-4TRBJ1-1) with cross-reactivity
with allo-HLA-B27, and showed an expansion of the CMV
NLV/HLA-A2 cross-reactive cells prior to CMV reactivation
in two lung transplant recipients (Nguyen et al. 2014).
However, it could not be confirmed whether the expansion of
the CMV-specific T cells in association with active CMV dis-
e a s e wa s a s s o c i a t e d w i t h c l i n i c a l l y d e f i n i t e
allo-B27-mismatched graft rejection (Nguyen et al. 2014;
Nguyen et al. 2013). Heutinck and colleagues showed that
virus-specific CD8 T cells that recognize both the cognate viral
epitope and donor cells are transiently present in the circulation
of kidney transplant recipients infected with CMV and EBV
(Heutinck et al. 2016). For example, in two HLA-B8+ recipi-
ents who received an HLA-B*44:02-mismatched graft, EBV
EBNA3A FLR/HLA-B8 cells were detectable in the peripheral
blood and remained responsive to donor alloantigen for up to
1 year post transplantation. However, the donor-reactive
virus-specific T cell levels declined after transplantation.
While a possible explanation for these findings is that the
virus-specific T cells migrated to the kidney allograft where
they could be harmful, the presence of cross-reactive T cells
was not associated with an inferior transplant outcome. The
clinical relevance of allo-human leukocyte antigen
cross-reactivity in mediating alloimmunity has also been
reviewed by Rowntree and colleagues (Rowntree et al. 2016).
We suggest that further studies examining the in vivo clinical
relevance of allo-HLA cross-reactivity by virus-specific T cells
in human transplant recipients are necessary.
TCR affinity of cross-reactive virus-specific T cells
for allo-HLA and the ability to mediate alloimmunity
During development, T cells undergo an instructional process
of positive and negative selection in the thymus, by deletion of
T cells from the Tcell repertoire that express TCRs with either
insufficient or too high affinity for self-HLA. As T cells only
encounter self-HLA molecules during their thymic education,
shaping of the TCR repertoire does not take into account
potential cross-reactivity against allo-HLA molecules.
Virus-specific memory T cell clonotypes can therefore theo-
retically cross-react to allo-HLAwith broad variation in TCR
affinity. Generally, high-affinity TCR-peptide-MHC (pMHC)
interactions are associated with more potent T cell activation
compared to low-affinity interactions (Bridgeman et al. 2012;
Holler and Kranz 2003; Stone et al. 2009). The differential
TCR-pMHC binding associated with variation in affinity in-
duces altered phosphorylation patterns in signaling pathways
downstream of the TCR (Madrenas et a l . 1995;
Sloan-Lancaster et al. 1994), resulting in more potent or even
qualitatively different effector functions (Auphan-Anezin
et al. 2006; Edwards and Evavold 2011; Jenkins et al. 2009;
Nel and Slaughter 2002). Accordingly, TCRs generally bind
with higher affinity to agonistic compared to antagonistic pep-
tides (Ely et al. 2005; Lyons et al. 1996). Nevertheless, excep-
tions to this rule have been described (Kersh et al. 1998) and
affinity is subjected to thresholds that prevent further improve-
ment of T cell functionality (Tan et al. 2015).
Variation in TCR affinity for allogeneic HLA ligands is
thus likely to infer differential allorecognition, thereby affect-
ing the potential for allograft rejection. For example, TCR
affinity has been investigated for the human EBV B8/FLR
cross-reactivity against allo-HLA-B*44:02. Using surface
plasmon resonance (SPR) and tetramer competition, the
TCR affinity for the alloepitope was shown to be significantly
lower compared to the cognate epitope (Macdonald et al.
2009), and to date, there is no conclusive evidence for allo-
graft rejection by EBV B8/FLR cross-reactive T cells in a
clinical setting. On the other hand, studies of cross-reactive
Tcells in mice have shown that TCR affinity was significantly
higher for the alloepitope compared to syngeneic epitopes
(Garcia et al. 1997), leading to potent alloreactive responses
in mice. It is evident that more cross-reactivity models should
be investigated to make any general statements on the strength
of TCR affinity towards the alloepitope—but unfortunately,
this research is hampered by the fact that TCR affinity studies
require comprehensive knowledge of the allopeptide, which is
lacking for most human virus-specific TCR cross-reactivities.
Although, in addition to co-stimulation, TCR affinity
shows an unmistakable correlation with T cell activation, ul-
timately the fate and quality of the T cell response is deter-
mined by TCR avidity, the accumulated strength of interaction
of all non-covalent binding at the Tcell surface. The quality of
the T cell response is a result of the kinetics of subsequent
TCR signaling (Sykulev 2010). Although TCR affinity is con-
sidered the most prominent determinant of TCR avidity, other
determinants play an important role in contributing to TCR
avidity as well: including CD4/CD8 co-receptor binding
(Laugel et al. 2007), MHC density on the target cell surface
(Corse et al. 2011), cluster formation of TCRs on the T cell
surface, the recruitment of signaling molecules to the
TCR-CD3 complex, and accessory molecules in lipid rafts
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(Alonso and Millán 2001). For example, the immunological
synapse provides an instrument to amplify signals down-
stream of lower-affinity TCR interactions, thereby enhancing
TCR signaling (Cemerski et al. 2007; Tailor et al. 2008).
Furthermore, inflammatory signals lead to the increase of sur-
faceMHC expression, thereby in theory increasing TCR avid-
ity for the alloepitope and the likelihood of generating an
alloresponse (Fig. 1). On the other hand, for in-depth charac-
terization of TCR-pMHC binding strength, TCR affinity mea-
surement remains the golden standard, determining that TCR
avidity under inflammatory and non-inflammatory circum-
stances may thus provide a biologically relevant surrogate to
estimate the binding strength between cross-reactive
virus-specific T cells and their allo-HLA target cells when
the cross-reactive allopeptide is unknown.
Finally, TCR affinity and avidity determine for a great part
TCR signaling required for T cell memory formation (Daniels
and Teixeiro 2015). The memory T cell population is of spe-
cial interest to transplantation, given that it has a lower activa-
tion threshold compared to the naive counterpart (Kimachi
et al. 2003), the requirement for co-stimulation is abolished,
and effector mechanisms are shaped to being most optimal for
eradicating virus-infected cells. Indeed, cross-reactive memo-
ry T cells have been shown to be able to lead to allograft
rejection in mice and pose a threat to tolerance induction
(Adams et al. 2003a). Interestingly, a recent report in mice
described that even low-affinity priming was able to generate
a cross-reactive memory T cell pool that rapidly induced re-
jection upon high-affinity graft challenge, illustrating the re-
markable potential of memory T cells to generate secondary
immune responses against cross-reactive epitopes regardless
of priming events (Krummey et al. 2016). Increasing the un-
derstanding of cross-reactive TCR affinity and avidity for
alloepitopes could thus provide better insight into the potential
threat of the alloreactive memory T cell compartment under
inflammatory and non-inflammatory circumstances.
Innate immunity
For a long time, solid organ rejection has been considered the
consequence of adaptive immunity from cellular and/or
antibody-mediated responses. However, there is now consis-
tent evidence that activation of innate immunity is necessary
prior to the initiation of allo-HLA-specific immune responses
and rejection. The activation of innate immunity following
invasion by infectious pathogens could therefore contribute
to allorecognition and graft rejection (Fig. 2).
Toll-like receptors
Toll-like receptors (TLRs) are pattern recognition receptors
that recognize highly conserved pathogen-derived molecules.
All TLRs transduce their signal via the activation of the
MyD88 protein with the exception of TLR3 which uses the
TRIF molecule. TLR1 is ubiquitously expressed and all TLRs
are expressed on epithelial cells and TLR5–10 are expressed
on endothelial cells and many graft parenchymal cells. TLR
activation as a consequence of pathogen infection is associat-
ed with potent activation of the innate immune system includ-
ing secretion of inflammatory cytokines and chemoattractants
and maturation and activation of donor and recipient
antigen-presenting cells. Therefore, TLRs could be an essen-
tial link between innate immunity and adaptive immune re-
sponses against alloantigens.
Activation of TLRs following pathogen infection is
thought to play a key role in the recruitment and activation
of alloreactive lymphocytes associated with graft rejection.
There is much support for this link in rodent models.
Induced tolerance to cardiac and skin allografts can be over-
come by injection of the TLR9 agonist CpG and the TLR2
agonist Pam3CysK (Chen et al. 2006; Porrett et al. 2008;
Thornley et al. 2006; Walker et al. 2006). Absence of the
MyD88 adaptor protein in both donor and recipient mice has
a lso been assoc ia ted wi th acceptance of minor
antigen-mismatched grafts (Goldstein 2011; Goldstein et al.
2003; Tesar et al. 2004).
Palmer and colleagues investigated the impact of two func-
tional polymorphisms in the TLR4 gene on the incidence of
acute rejection after lung transplantation (Palmer et al. 2003).













Fig. 1 The avidity of virus-induced cross-reactive T cells for a specific
HLA alloantigen may depend on the expression of that particular HLA
molecule. A higher expression will increase the avidity
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and Thr399Ile polymorphisms, both of which are associated
with endotoxin hyporesponsiveness. The rate of acute
rejection at 6 months was significantly reduced in recipients
































Allograft dysfunction or loss
Fig. 2 Infectious agents can
activate innate immunity via
different pathways, which among
others may lead to a more
efficient presentation of the
allogeneic HLA molecules to T
cells and B cells
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type. These results strongly suggest that activation of innate
immunity following endotoxin exposure via TLR4 signaling
contributes to the development of acute lung transplant graft
rejection. More generally, activation of the many different
damage-associated molecular pattern (DAMP) receptors and/
or pathogen-associated molecular pattern (PAMP) receptors,
as a consequence of local or systemic infection, could be as-
sociated with increased risk of adaptive immunity and
allorecognition. This mechanism may be particularly relevant
in lung transplantation given the large pathogen burden and
regular exposure to the foreign environment.
Pro-inflammatory cytokines and chemokines
Active allograft infection can trigger graft infiltration, activa-
tion of the cells of the innate immune system, and secretion of
many different pro-inflammatory cytokines. IL-1, IL-6, IL-12,
TNF, and IFNα/γ, among many other cytokines and
chemokines, can all lead to graft inflammation, activation of
adaptive immunity, and cytotoxicity.
Pro-inflammatory cytokines produced following infection
can abrogate tolerance induction and even break established
tolerance to an allograft in mouse models. Exogenous IL-1
administration at the time of transplant can prevent tolerance
induction to skin and islet allografts (Holan 1988; Sandberg
et al. 1993). In key experiments, it has been shown that
IL1-receptor blockade can impair donor-specific DTH, reduce
corneal graft infiltration by antigen-presenting cells, and ab-
rogate second set rejection of skin allografts (Dana et al. 1998;
Dana et al. 1997; Dekaris et al. 1999; Yamada et al. 1998;
Yamada et al. 1999; Yamada et al. 2000), suggesting that
IL1 production is inextricably linked with antigen presenta-
tion and adaptive immunity to allografts in mice models.
IL-6 and TNFα enhance pro-inflammatory immunity and
render T cells resistant to suppression by Tregs, and their
deficiency renders mice susceptible to tolerance induction
via co-stimulation blockade (Goldstein 2011; Goldstein et al.
2003; Walker et al. 2006). IL-6 can prevent transplant toler-
ance to cardiac allografts by promoting the differentiation and
activation of CD8+ T cells of the Th17 phenotype (Burrell
et al. 2008). Likewise, type 1 interferons have been shown
to confer resistance to tolerance. For example, tolerance resis-
tance following L. monocytogenes infection, despite
co-stimulation blockade, is dependent on production of inter-
feron α and β (Thornley et al. 2007).
GvHD is a complication of allogeneic bone marrow trans-
plantation whereby donor-derived T cells recognize and dam-
age recipient tissue. In the human hematopoietic stem cell
transplantation (HSCT) setting, GvHD has been associated
with both IL-6 production and also active CMV replication.
Hill and colleagues administered the IL-6 inhibitor tocilizimab
to HSCT recipients, in addition to standard GvHD prophylax-
is, and showed lower rates of acute GvHD (Kennedy et al.
2014). Results presented by this group confirm that an inflam-
matory cytokine produced following viral infection can lead
to adaptive T cell responses against allogeneic HLA.
Furthermore, these results suggest that therapeutic inhibition
of cytokines or chemokines may be a potential target to pre-
vent HLA-specific T cell alloresponses.
Antigen presentation
After phenotypic transition, antigen uptake, and migration to
lymphoid tissues, antigen-presenting cells can present alloan-
tigens to immunocompetent cells of the adaptive immune sys-
tem. Antigen-presenting cells (APCs) that, following antigen
uptake, undergo maturation in an inflammatory environment
and/or after exposure to pathogen-associated molecular pat-
terns (PAMPs), such as occurs in the presence of active infec-
tion, express high levels of HLA class II and co-stimulatory
molecules and are potent inducers of alloimmunity (Rogers
and Lechler 2001). After APC activation, T cells can recog-
nize and exhibit effector function against allogeneic HLA via
direct allorecognition (TCR recognizes intact allogeneic HLA
on the surface of the donor cell) or indirect allorecogniton
(TCR recognizes peptide fragments from allo-HLA presented
on the surface of autologous APCs).
Currently, it is not proven that active infection, like BK
virus infection, and subsequent activation of intra-graft
antigen-presenting cell function of either donor APCs (direct
allorecogniton) or recipient APCs (indirect allorecognition)
can definitely trigger de novo allo-HLA-specific T
cell-mediated allorecognition. However, APCs represent an
essential link between innate and adaptive alloimmunity, and
it is likely that APCs activated following infection are able to
provide critical co-stimulatory signals and cytokines both at
the site of grafting and in the recipient’s lymphoid tissues, and
to also serve as APCs for alloantigen presentation to T cells.
Taken together, therapies aimed at inhibiting innate im-
mune activation following infectious pathogens may also rep-
resent a novel means to prevent adaptive immunity against
allogeneic tissues.
Viral infections and anamnestic B cell responses
The relationship between viral infections and ensuing HLA
antibody production is controversial, and may be dependent
on the type of pathogen assessed, whether active infection or
vaccination is studied, as well as the definition of a positive
result in HLA antibody screenings (Roelen et al. 2012). Many
of the reports on the development of HLA antibodies after viral
infections are anecdotal, with large controlled and prospective
studies on the subject lacking. Regardless, the majority of data
in favor of HLA antibody formation upon viral infection or
vaccination hint towards activation of pre-existing memory B
cells, with an increase in breadth and strength of HLA
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antibodies as a result.When taking into account the triggers that
can lead to memory B cell activation, viral infections certainly
have the potential to result in bystander memory B cell activa-
tion. First of all, B cells display various TLRs, which as de-
scribed above can lead to immune cell activation. TLR ligands
such as CpG oligodeoxynucleotides (TLR9) and R-848
(Resiquimod, TLR7-8) are often used in the laboratory for
polyclonal B cell activation, with the latter being particularly
effective at activating memory B cells (Karahan et al. 2014;
Pinna et al. 2009). It is therefore conceivable that similar signals
could lead to activation of B cells, regardless of their antigen
specificity in vivo. Secondly, cytokines produced upon viral
infection as described above could lead to B cell activation
(Bonig et al. 1998; Vilchez et al. 2002) and work in concert
with TLR signaling. Alternatively, there may be heterologous
immunity on the level of B cells analogous to T cells, which
could result in HLA antibody formation due to epitope similar-
ity with viral antigens. The latter has not yet formally been
proven, and will require extensive screening of HLA antibodies
towards panels of viral antigens.
There are several reports of elevated plasma cell infiltrates
and C4d positivity in biopsies from renal transplant recipients
that experience a viral infection coinciding with acute rejec-
tion (Aiello et al. 2004; Forman et al. 2004; Khakhar et al.
2003). These plasma cell infiltrates could be due to local dif-
ferentiation of memory B cells towards plasma cells, as has
been shown for chronic rejection as well (Thaunat et al. 2005).
A study which systematically addressed the relation between
viral infections and HLA antibodies in 35 sensitized renal
transplant waitlist patients and 42 patients transplanted after
desensitization showed that increases in strength and breadth
of HLA antibodies upon viral infection were common (97 and
55%, respectively). The increase in the breadth of HLA anti-
bodies was mainly within the same cross-reactive antigen
group (CREG), indicating an expansion of existing specific-
ities without development of new specificities (Locke et al.
2009). Interestingly, a study focusing on the opposite scenario
of possible elevation in virus-specific antibody titers upon
HLA antibody formation showed that in this situation, the
humoral immune response remained HLA specific without
an increase in titers of virus-specific antibodies (Krishnan
et al. 2013). This might be due to the nature of the activation
signals, such as the lack of PAMPS in the setting of
allorecognition.
HLA antibody formation upon vaccination has been studied
in more detail, albeit no firm conclusions can be drawn (Roddy
et al. 2005). When considering influenza vaccination, several
studies showed no effect on HLA antibody formation at all
(Candon et al. 2009; Kimball et al. 2000), whereas other studies
did show a significant percentage of renal transplant recipients
developing anamnestic B cell responses and de novo HLA
antibodies (Fairhead et al. 2012; Katerinis et al. 2011). The
latter report was on a prospective vaccination study including
151 renal transplant recipients of which 15% of patients subse-
quently developed HLA antibodies, many of them being de
novo. Only 12 patients had been immunized previously as de-
termined by HLA antibody positivity at study onset (Katerinis
et al. 2011). This indicates either that true de novo HLA anti-
bodies were formed, possibly due to heterologous immunity, or
that a previously undetected B cell memory existed in these
patients. Indeed, an HLA-specific B cell memory in the absence












B) Bystander activation model
Fig. 3 Infectious agents may
affect the humoral immune
response to allogeneic HLA either
by inducing cross-reactive
antibodies or by triggering an
anamnestic memory B cell
response
Immunogenetics (2017) 69:631–641 637
(Karahan et al. 2015a; Snanoudj et al. 2015). Of note, in pa-
tients that experienced an increase in the breadth of HLA anti-
bodies, non-DSA was again directed at epitopes shared with
donor HLA antigens, although not exclusively (Katerinis
et al. 2011). Another study on influenza vaccination in renal
transplant recipients reported only de novo HLA antibody for-
mation after vaccination in 12% of patients (Fairhead et al.
2012). Interestingly, all patients that produced de novo HLA
antibodies were female, in whom memory B cells due to prior
pregnancies may have been present.
When considering all data published, it is clear that infec-
tion or vaccination may lead to anamnestic memory B cell
responses (Fig. 3). It is pivotal to determine what these cir-
cumstances are and how memory B cell activation can be
prevented. Novel tools to monitor HLA-specific memory B
cells will certainly allow to do so (Han et al. 2009; Heidt et al.
2012; Karahan et al. 2015b).
Conclusions
Taken together, recent scientific evidence supports the hypothesis
that infectious pathogens may have a significant impact on the
rate of solid organ rejection, and are likely to be amajor barrier to
successful transplant tolerance, via multiple immunological
mechanisms (Amir et al. 2010; Benichou et al. 2012).
It is now firmly established that innate immunity responses
triggered after transplantation, as a consequence of tissue
damage and infections, can be an essential element of the
inflammatory process leading to graft rejection. This review
supports the view that activation of the various components of
the innate immune system can lead to activation and recruit-
ment of adaptive immunity and transplant rejection. This pro-
cess can be mediated by TLRs, cytokines, chemokines, and
complement and/or antigen-presenting cells. Taken together,
these results suggest that tolerance induction protocols will
require agents capable of specifically suppressing innate im-
mune responses that are associated with allorecognition, while
at the same time not suppressing components of the innate
immune system, such as DCs, that are required for transplant
tolerance induction (Benichou et al. 2012).
It is undoubted that virus-specific memory T cells are able to
exert in vitro allo-HLA-specific reactivity; however, in vivo func-
tional activity of virus-specific memory Tcells against allo-HLA
is lacking and should be amajor focus for investigation.Memory
T cells are long-lived, broadly distributed, capable of homing to
areas of inflammation, and are rapidly activated after stimulation
to exert potent effector function and do remain in the tissue as
resident memory lymphocytes. Recent studies have established
resident memory T cells as the dominant lymphocyte population
surveying most non-lymphoid tissues such as organs. Therefore,
their rapid effector function, lower activation requirements, and
tissue location suggest that pathogen-specific memory T cells
may be a principle mediator of acute and chronic allograft rejec-
tion (Beura et al. 2016).
The role of pathogen-specific T cell tissue migration and res-
idency has not been extensively studied in solid organ transplan-
tation but should also become a major focus of investigation.
Novel techniques that now allow the tracking of donor-reactive
memory T cells may finally be able to determine the clinical
relevance of pathogen-specific T cells to allorecognition in the
solid organ transplant setting (Beura et al. 2016; Krams et al.
2016; Morris et al. 2015). Accumulating evidence suggests that
memory T cells have survival advantages over their counterparts
and are more resistant to immunosuppressive medications and
lymphoablation, and therefore, if pathogen-specific memory T
cells are indeed able to mediate alloreactivity then selective ther-
apies to inhibit alloreactive memory Tcells are required (Nicosia
and Valujskikh 2016; Valujskikh et al. 2010; Valujskikh and Li
2007). The implications of resident memory Tcells for transplan-
tation have been extensively reviewed by Beura et al. (2016).
It is likely that infections and vaccinations can induce an-
amnestic B cell responses in previously sensitized individuals;
however, the ability for infections to induce de novo
allo-HLA-specific B cells and antibodies is still uncertain
but does require further investigation. New tools developed
to monitor HLA-specific B cell responses will provide new
insights into the impact of pathogen exposure on the
alloreactive B cell repertoire and should help answer some
of these important questions (Han et al. 2009; Heidt et al.
2012; Karahan et al. 2015b; Karahan et al. 2014).
Therefore, we argue that infections and vaccinations can
stimulate anti-graft responses via multiple mechanisms and
could be a major barrier to transplant tolerance. The in vivo
relevance of infection and vaccination to allo-HLA-specific
reactivity should be a major focus for investigation, and could
have major therapeutic implications for treatment of solid or-
gan rejection and induction of transplant tolerance.
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